Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 1Glioma 1Colorectal Adenocarcinoma 1Brain Neoplasms 1Anxiety Disorders 1

Interventions

Music Therapy 7Cognitive Behavioral Therapy 6Surveys and Questionnaires 4Standard of Care 4Saline Solution 4Hypnosis 4Esketamine 4Therapeutics 3Psilocybin 3Palliative Care 2Methods 2Cannabidiol 2Art Therapy 2nabiximols 1Waiting Lists 1Videotape Recording 1Transcutaneous Electric Nerve Stimulation 1Transcranial Direct Current Stimulation 1Timbre Perception 1Sertraline 1Self-Help Groups 1Selective Serotonin Reuptake Inhibitors 1Respiration 1Relaxation Therapy 1Referral and Consultation 1Psychotherapy 1Psychosocial Intervention 1Psychiatric Rehabilitation 1Population Groups 1Pharmaceutical Preparations 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anxiety Disorders × Fluoxetine × 1 year × Clear all
NCT07174947 2026-03-24

SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety

First Affiliated Hospital of Wenzhou Medical University

Phase 2 Recruiting
240 enrolled

Anxiety Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡